Dare Bioscience Inc. [NASDAQ: DARE] surged by $0.18 during the normal trading session on Wednesday and reaching a high of $1.38 during the day while it closed the day at $1.34. The company report on January 9, 2023 that Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause.
DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy.
Dare Bioscience Inc. stock has also gained 17.54% of its value over the past 7 days. However, DARE stock has inclined by 39.03% in the 3 months of the year. Over the past six months meanwhile, it has gained 26.42% and gained 61.45% year-on date.
The market cap for DARE stock reached $111.22 million, with 84.82 million shares outstanding and 83.16 million shares in the current float. Compared to the average trading volume of 234.16K shares, DARE reached a trading volume of 2694882 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Dare Bioscience Inc. [DARE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DARE shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DARE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Dare Bioscience Inc. is set at 0.06, with the Price to Sales ratio for DARE stock in the period of the last 12 months amounting to 11.12. The Price to Book ratio for the last quarter was 4.32, with the Price to Cash per share for the same quarter was set at 0.49.
DARE stock trade performance evaluation
Dare Bioscience Inc. [DARE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.54. With this latest performance, DARE shares gained by 54.11% in over the last four-week period, additionally plugging by 26.42% over the last 6 months – not to mention a drop of -8.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DARE stock in for the last two-week period is set at 79.24, with the RSI for the last a single of trading hit 83.31, and the three-weeks RSI is set at 75.08 for Dare Bioscience Inc. [DARE]. The present Moving Average for the last 50 days of trading for this stock 0.9719, while it was recorded at 1.1810 for the last single week of trading, and 1.0950 for the last 200 days.
Dare Bioscience Inc. [DARE]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -205.82, with Return on Assets sitting at -122.15.
Dare Bioscience Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.
Dare Bioscience Inc. [DARE]: Insider Ownership positions
There are presently around $10 million, or 9.30% of DARE stock, in the hands of institutional investors. The top three institutional holders of DARE stocks are: VANGUARD GROUP INC with ownership of 3,533,563, which is approximately 0.865% of the company’s market cap and around 1.96% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 819,223 shares of the stock with an approximate value of $1.1 million in DARE stocks shares; and BLACKROCK INC., currently with $0.95 million in DARE stock with ownership of nearly -0.772% of the company’s market capitalization.
Positions in Dare Bioscience Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 17 institutional holders increased their position in Dare Bioscience Inc. [NASDAQ:DARE] by around 876,865 shares. Additionally, 10 investors decreased positions by around 498,255 shares, while 9 investors held positions by with 6,419,109 shares. The mentioned changes placed institutional holdings at 7,794,229 shares, according to the latest SEC report filing. DARE stock had 2 new institutional investments in for a total of 13,782 shares, while 6 institutional investors sold positions of 182,960 shares during the same period.